Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds

Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds, currently does not have specific carbon emissions data available for the most recent year. The organisation is part of a corporate family that cascades emissions data from Thermo Fisher Scientific Inc., which is at cascade level 6. However, no specific emissions figures or reduction targets have been provided.

In terms of climate commitments, Eli Lilly & Co. has not outlined any specific reduction initiatives or targets, such as those set by the Science Based Targets initiative (SBTi). The absence of documented reduction targets suggests that the company may still be in the early stages of formalising its climate strategy.

As a merged entity, Eli Lilly & Co. may benefit from the climate initiatives and commitments of its parent organisation, Thermo Fisher Scientific Inc. However, without explicit data or targets, it is challenging to assess the company's current carbon footprint or its long-term climate strategy.